Deciphera Pharmaceuticals - Top 20 VC deals of 2007

Company: Deciphera Pharmaceuticals
Based: Lawrence, KA
Amount: $41.5
Investor:
Kansas Technology Enterprise Corporation

Scoop: Deciphera Pharmaceuticals is developing drugs to attack the molecular cause of Alzheimer's disease, rheumatoid arthritis, asthma and other diseases. The company has two programs. DCC-2036 is a bcr-Abl inhibitor now in preclinical development for the management of treatment-resistant or intolerant chronic myeloid leukemia. Deciphera has recently applied its unique approach to kinase inhibitor design to B-Raf kinase. It is also pursuing two strategies centered on B-Raf inhibition.

Deciphera Pharmaceuticals - Top 20 VC deals of 2007
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i